Skip to main content

Table 3 Associations of DNA methylation aging markers with all-cause mortality

From: Whole blood DNA methylation aging markers predict colorectal cancer survival: a prospective cohort study

Markers

Categories

All stages

Stage I and II

Stage III

Stage IV

P for interaction

ndeath/ncases

HR (95% CI)*

ndeath/ncases

HR (95% CI)#

ndeath/ncases

HR (95% CI)#

ndeath/ncases

HR (95% CI)#

AgeAccelHorvath

Tertile 1

361/736

1.00 (Ref.)

135/364

1.00 (Ref.)

124/260

1.00 (Ref.)

100/107

1.00 (Ref.)

Tertile 2

339/736

1.01 (0.86, 1.18)

138/402

0.97 (0.76, 1.24)

109/236

0.95 (0.73, 1.25)

87/92

1.14 (0.83, 1.55)

Tertile 3

379/734

1.17 (0.99, 1.38)

163/393

1.32 (1.04, 1.38)

117/230

1.18 (0.90, 1.55)

98/110

0.98 (0.71, 1.34)

Per SD increase

1079/2206

1.06 (0.99, 1.13)

436/1159

1.10 (0.99, 1.21)

350/726

1.10 (0.99, 1.23)

285/309

0.96 (0.84, 1.10)

0.139

AgeAccelHannum

Tertile 1

327/736

1.00 (Ref.)

128/386

1.00 (Ref.)

124/268

1.00 (Ref.)

74/80

1.00 (Ref.)

Tertile 2

340/736

0.93 (0.78, 1.09)

126/387

0.89 (0.69, 1.15)

109/235

0.93 (0.70, 1.24)

103/111

0.86 (0.60, 1.24)

Tertile 3

412/734

1.12 (0.94, 1.33)

182/386

1.18 (0.91, 1.53)

117/223

1.14 (0.84, 1.55)

108/118

0.91 (0.62, 1.34)

Per SD increase

1079/2206

1.06 (0.98, 1.14)

436/1159

1.05 (0.93, 1.17)

350/726

1.11 (0.98, 1.26)

285/309

1.00 (0.86, 1.17)

0.475

DNAmMRscore

Tertile 1

275/736

1.00 (Ref.)

102/410

1.00 (Ref.)

97/242

1.00 (Ref.)

76/84

1.00 (Ref.)

 

Tertile 2

346/736

1.07 (0.89, 1.30)

147/399

1.27 (0.94, 1.70)

104/231

0.97 (0.71, 1.34)

92/102

0.89 (0.61, 1.29)

 

Tertile 3

458/734

1.66 (1.32, 2.09)

187/350

2.01 (1.42, 2.85)

149/253

1.64 (1.13, 2.38)

117/123

1.33 (0.87, 2.04)

Per SD increase

1079/2206

1.34 (1.20, 1.49)

436/1159

1.50 (1.28, 1.76)

350/726

1.39 (1.18, 1.64)

285/309

1.09 (0.90, 1.33)

0.616

AgeAccelPheno

Tertile 1

318/736

1.00 (Ref.)

122/390

1.00 (Ref.)

123/263

1.00 (Ref.)

71/80

1.00 (Ref.)

Tertile 2

323/736

1.02 (0.86, 1.20)

126/395

0.89 (0.68, 1.15)

99/234

0.92 (0.69, 1.22)

96/102

1.43 (1.02, 2.01)

Tertile 3

438/734

1.35 (1.14, 1.59)

188/374

1.50 (1.17, 1.92)

128/229

1.28 (0.98, 1.69)

118/127

1.31 (0.93, 1.86)

Per SD increase

1079/2206

1.18 (1.10, 1.27)

436/1159

1.22 (1.11, 1.35)

350/726

1.20 (1.07, 1.35)

285/309

1.12 (0.97, 1.30)

0.459

AgeAccelGrim

Tertile 1

286/736

1.00 (Ref.)

98/405

1.00 (Ref.)

119/258

1.00 (Ref.)

68/72

1.00 (Ref.)

Tertile 2

347/736

1.13 (0.94, 1.34)

144/381

1.34 (1.00, 1.78)

106/246

0.98 (0.73, 1.32)

95/104

0.95 (0.66, 1.37)

Tertile 3

446/734

1.65 (1.37, 2.00)

194/373

2.30 (1.69, 3.13)

125/222

1.63 (1.19, 2.22)

122/133

1.01 (0.71, 1.45)

Per SD increase

1079/2206

1.35 (1.24, 1.47)

436/1159

1.48 (1.31, 1.66)

350/726

1.24 (1.08, 1.43)

285/309

1.23 (1.05, 1.44)

0.082

  1. AgeAccel, age acceleration; CI, confidence interval; DNAm, DNA methylation; HR, hazard ratio; MRscore, mortality risk score
  2. Numbers printed in bold: statistically significantly different from 1 (P < 0.05)
  3. *Overall HR was adjusted for age, sex, batch effects, tumor stage and leukocyte composition (Houseman’s algorithm)
  4. #Stage-specific HR was adjusted for age, sex, batch effects and leukocyte composition (Houseman’s algorithm)